Revealing How Blood Triggers Brain Disease

In patients with neurological diseases like Alzheimer’s disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment. These harmful immune cells may also contribute to age-related cognitive decline in people without dementia.

Read more here.

 

 

Nature Immunology Selected Our Image For The July 2023 Volume 24 Cover

Katerina Akassoglou and colleagues provide single-cell RNA-sequencing and phosphoproteome analyses of CNS microglia and macrophages in response to blood proteins including activated complement and fibrin. Their findings point to potential therapeutic targeting of microglia activation by immune and vascular signals.

Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease

Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the initiation of first-in-human dosing for a Phase 1 trial of its lead asset THN391, a fibrin-targeting therapeutic candidate for Alzheimer’s disease.

Read the full article here.

Exclusive: Therini raises $36M, will target fibrin protein for Alzheimer’s and diabetic macular edema

Therini Bio has raised a $36 million Series A and will head to the clinic with an antibody that neutralizes fibrin, a blood clotting protein, that it hopes could have broad applications in tamping down inflammation.

Read more here.